Deletion of PINK1 may make breast cancer cells sensitive to paclitaxel and NSCLC cells sensitive to cisplatin, while PINK1 overexpression can counteract this sensitization and result in chemical resistance (Zhang et al., 2017). This evidence concerns the gene PINK1 and breast cancer.